Comparison of the TaqMan and LightCycler systems in pharmacogenetic testing: evaluation of CYP2C9*2/*3 polymorphisms.

摘要

BACKGROUND: Pharmacogenetic testing for drug-metabolizing enzymes is not yet widely used in clinical practice. METHODS: In an attempt to facilitate the application of this procedure, we have compared two real-time PCR-based methods, the TaqMan and the LightCycler for the pharmacogenetic evaluation of CYP2C9*2/*3 polymorphisms. RESULTS AND CONCLUSION: Both procedures are suitable for pharmacogenetic studies. The TaqMan procedure was less expensive in terms of cost per sample, but the TaqMan apparatus is more expensive than the LightCycler apparatus.